Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfaclozine, also known as sulfachloropyrazine, is a small molecule sulfonamide antibiotic and anticoccidial agent used primarily in veterinary medicine. It functions as a competitive antagonist of para-aminobenzoic acid (PABA), thereby inhibiting the enzyme dihydropteroate synthase (DHPS). This inhibition prevents the synthesis of dihydrofolic acid, a critical precursor for folic acid in bacteria and protozoa, leading to bacteriostatic and coccidiostatic effects. It is particularly effective against the second generation of coccidia cleavage. Sulfaclozine is indicated for the treatment of various poultry diseases, including coccidiosis (caused by *Eimeria* species), colibacteriosis, fowl cholera (*Pasteurella multocida*), and fowl typhoid (*Salmonella gallinarum*). It is also utilized in sheep and goats for the management of coccidiosis and is typically administered as a water-soluble powder via drinking water.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfaclozine.